Showing results (31-40 of 37) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2005
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumoursKlaus Mross, Joachim Drevs, Marianne Müller, et al.Anti-Cancer Drugs|April 20, 2004
Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR)Klaus Mross, Max E Scheulen, Thomas Licht, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxelAnja Henningsson, Sharon Marsh, Walter J Loos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumorsJoachim Drevs, Patrizia Siegert, Michael Medinger, et al.Journal of Angiogenesis Research|December 1, 2009
DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I studyKlaus Mross, Ulrike Fasol, Annette Frost, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancerStephen Chan, Max E Scheulen, Stephen Johnston, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2003
Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studiesBruno Morgan, Anne L Thomas, Joachim Drevs, et al.Pageof 4